FDA approval for a new indication for Wegovy (semaglutide) to reduce the risk of major adverse cardiovascular events, including cardiovascular death, heart attack, and stroke, in adults with cardiovascular disease and obesity or overweight
Both help with blood sugar control and appetite suppression but come with side effects like nausea and stomach discomfort
The following timeline, based on clinical trial data from Eli Lilly, shows the typical progression: Appetite suppression typically begins around day 3 of the first dose, with significant feelings of fullness developing by week 2
10.1016/S0140-6736(05)61359-1
Three FDA-approved medications are covered: Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (orforglipron, the first oral GLP-1 pill for weight loss)